Latest Reports in Life Science Research Global Library: Western Europe

« Back to Activities

Published: 24 Feb 2016

The Life Sciences has a major position in the economies of Western Europe and all the 17 countries covered in this report (ABA 374.3) have put Biotechnology high up the list of priorities within science. The problem has been, and remains, that economic issues have limited funding and even the EC has taken funds from the Horizon 2020 programme. Individual countries are overcoming these economic issues led by the UK, Germany and some of the Scandinavian countries with major changes to the markets during 2015. The technology advances of Next generation Sequencing and Genetic Modulation through CRISP technology are also rapidly changing the market applications and product uses. This new report covers the whole market up to the end of December 2015 and the 2016 budgets where available with projections for Applications and Product markets out to 2020 in line with other reports covering the Middle East, Africa and the Far East countries. The Contents Lists and Abstracts can be seen on the Latest Reports page of the web site for Western Europe, ABA 374.3, as well as all the other reports.

The rapid market growth at the turn of the century in these Western European countries has now slowed, partly because of the economic situation throughout the world and the specific issues within the EU countries. A specific impact has been the reluctance of venture capital companies to support higher risk, longer term investments such as in Biotechnology. In addition, the rapid expansion of research groups in all segments of the market has now reached close to the more mature level required for countries to pursue their designated strategies.

Starting in 2014 and continuing into the first half of 2015 the venture capital organisations changed their view of Biotechnology and added a massive increase to the funding available, through start-ups, on-going companies and through supporting IPOs. This funding allowed an increase in the annual expenditure on products by companies and an increase in out-sourcing for particular services and BioInformatics. The improved economic position has also allowed funding to be released to support consolidation within the sector in 2015. For example, ThermoFisher completed integration of LifeTechnologies and at year end agreed to buy Affymetrix, MerckKgaA completed acquisition of SigmaAldrich and there were many acquisitions of small businesses by these and other companies.

Although Red (Healthcare related) Biotechnology dominates the applications there are many other areas as detailed in the report for each country and an indication of the breadth of applications in the region is shown below.

Application Areas in Western Europe, 2013-2020.

View the Contents List & Abstract here

An impetus for growth has come from technology developments at a time when relatively well established technologies are already showing signs of early to even late maturity with lower prices and increased competition from local or small suppliers. The very rapid development of CRISPR technology has driven growth in DNA Analysis and Modifications as well as in Cell Based assays at the same time that there has been a strong commercial and research push to develop Next Gen Sequencing for diagnostic uses. The development curves for the various technologies are indicated in the chart below which is from the report.

Technology Development Status in Europe 2015.

The Economic and Political aspects that impact the funding for Life Science research are examined in detail with the base line for market and product quantification based on the events and budgets announced for 2015/16. This gives 2015 as the base line for market quantification so that projections for 2020 are valid and can be used to develop effective plans for the immediate future and into 2017

As in every region the key factors of importance in the Life Science research sector in these countries stem from the funding and are usefully compared with the development of the North American and Far East markets. The figures from the report demonstrate the driving forces in 2015 and the change since 2013.

The Version 3 report ABA 374.3 provides details of the 2015 markets and their quantification with projections to 2020.

View the Contents List & Abstract here